IE
GALT icon

Israel Englander’s Galectin Therapeutics GALT Stock Holding History

Israel Englander’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-87,000
Closed -$1.33M – 3573
2014
Q1 		$1.33M Buy
+87,000
New +$1.24M ﹤0.01% 2056

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Israel Englander's GALT Position: Q2 2026 in Review

Israel Englander reduced its Galectin Therapeutics (GALT) stake by 96% in Q2 2026, selling an estimated $1.98M and leaving 35,863 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #5368.

Israel Englander first reported a position in GALT in Q1 2014 and has held it in 35 quarters since. The position peaked at $2.23M in Q1 2026. 97 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Israel Englander held 35,863 shares of Galectin Therapeutics worth $166K as of Q2 2026.
  • Israel Englander sold 762,571 Galectin Therapeutics shares in Q2 2026, an estimated $1.98M.
  • Galectin Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5368 holding.
  • Israel Englander first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 35 quarters since.
  • Israel Englander's Galectin Therapeutics position peaked at $2.23M in Q1 2026.
  • 97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.